Jamjoom Pharmaceuticals Factory Company

SASE:4015 Stock Report

Market Cap: ر.س10.9b

Jamjoom Pharmaceuticals Factory Balance Sheet Health

Financial Health criteria checks 6/6

Jamjoom Pharmaceuticals Factory has a total shareholder equity of SAR1.4B and total debt of SAR0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are SAR1.9B and SAR412.8M respectively. Jamjoom Pharmaceuticals Factory's EBIT is SAR371.3M making its interest coverage ratio 3564.4. It has cash and short-term investments of SAR121.8M.

Key information

0%

Debt to equity ratio

ر.س0

Debt

Interest coverage ratio3564.4x
Cashر.س121.82m
Equityر.س1.44b
Total liabilitiesر.س412.83m
Total assetsر.س1.86b

Recent financial health updates

No updates

Recent updates

Jamjoom Pharmaceuticals Factory Company's (TADAWUL:4015) Business Is Yet to Catch Up With Its Share Price

Dec 17
Jamjoom Pharmaceuticals Factory Company's (TADAWUL:4015) Business Is Yet to Catch Up With Its Share Price

Getting In Cheap On Jamjoom Pharmaceuticals Factory Company (TADAWUL:4015) Is Unlikely

Apr 30
Getting In Cheap On Jamjoom Pharmaceuticals Factory Company (TADAWUL:4015) Is Unlikely

Financial Position Analysis

Short Term Liabilities: 4015's short term assets (SAR1.1B) exceed its short term liabilities (SAR334.9M).

Long Term Liabilities: 4015's short term assets (SAR1.1B) exceed its long term liabilities (SAR77.9M).


Debt to Equity History and Analysis

Debt Level: 4015 is debt free.

Reducing Debt: 4015 has no debt compared to 5 years ago when its debt to equity ratio was 3.7%.

Debt Coverage: 4015 has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: 4015 has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 22:29
End of Day Share Price 2024/12/26 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Jamjoom Pharmaceuticals Factory Company is covered by 4 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Madhu AppissaAl Rajhi Capital
null nullJ.P. Morgan
Tarek SleimanJ.P. Morgan